Alan S. Hazell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alan S. Hazell has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Dongmei Wang
Department of Medicine, University of Montreal, Montreal, Quebec, Canada
5 shared publicationsRaghu Vemuganti
Department of Neurological Surgery, University of Wisconsin, Madison, WI, USA
4 shared publicationsClaudia Zwingmann
Department of Medicine, University of Montreal, Montreal, Quebec, Canada
3 shared publications- Vinicius Rodrigues Silva
Department of Morphology and Pathology, Jundiaí Medical School, Jundiaí 13202-550, Brazil
3 shared publications Chunlei Wang
Department of Medicine, University of Montreal, Montreal, Quebec, Canada
2 shared publicationsDavid V. Pow
Department of Physiology and Pharmacology, University of Queensland, Brisbane, Australia
2 shared publications
Latest Publications
- 1 January 2018
- Published by Elsevier in Neurochemistry International
- Vol. 112, 134-145
Potential for stem cell treatment in manganism
- 1 January 2018
- Published by Elsevier in Neurochemistry International
- Vol. 112, 134-145
Potential for stem cell treatment in manganism
- 1 August 2017
- Published by Elsevier in Neuroscience Letters
- Vol. 656, 58-64
Acute liver failure is associated with altered cerebral expression profiles of long non-coding RNAs
- 1 August 2017
- Published by Elsevier in Neuroscience Letters
- Vol. 656, 58-64
Acute liver failure is associated with altered cerebral expression profiles of long non-coding RNAs
- 1 March 2017
- Published by Elsevier in Neuroscience Letters
- Vol. 642, 163-167
Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy
- 1 March 2017
- Published by Elsevier in Neuroscience Letters
- Vol. 642, 163-167
Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy
- Open Access
- 23 August 2016
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 7, 118
The Vegetative State and Stem Cells: Therapeutic Considerations
The vegetative state, also known as “unresponsive wakefulness syndrome”, is considered one of the most devastating outcomes of acquired brain injury. While diagnosis of this condition is generally well-defined clinically, patients often appear to be awake despite an absence of behavioural signs of awareness, which to the family can be confusing, leading them to believe the loved one is aware of their surroundings. This inequality of agreement can be very distressing. Currently, no cure for the vegetative state is available, as a result patients may remain in this condition for the rest of their lives, which in some cases amount to decades. Recent advances in stem cell approaches for the treatment of other neurological conditions may now provide an opportunity to intervene in this syndrome. This mini review will address development of the vegetative state, its diagnosis, affected cerebral structures, and the underlying basis of how stem cells can offer therapeutic promise that would take advantage of the often long-term features associated with this maladie to effect a repair of the severely damaged circuitry. In addition, current limitations of this treatment strategy including a lack of animal models, absence of long-term basic and clinical studies that might identify benefits of stem cell treatment, and the potential for development of tumors are considered.
- 23 August 2016
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 7, 118
Open AccessThe Vegetative State and Stem Cells: Therapeutic Considerations
The vegetative state, also known as “unresponsive wakefulness syndrome”, is considered one of the most devastating outcomes of acquired brain injury. While diagnosis of this condition is generally well-defined clinically, patients often appear to be awake despite an absence of behavioural signs of awareness, which to the family can be confusing, leading them to believe the loved one is aware of their surroundings. This inequality of agreement can be very distressing. Currently, no cure for the vegetative state is available, as a result patients may remain in this condition for the rest of their lives, which in some cases amount to decades. Recent advances in stem cell approaches for the treatment of other neurological conditions may now provide an opportunity to intervene in this syndrome. This mini review will address development of the vegetative state, its diagnosis, affected cerebral structures, and the underlying basis of how stem cells can offer therapeutic promise that would take advantage of the often long-term features associated with this maladie to effect a repair of the severely damaged circuitry. In addition, current limitations of this treatment strategy including a lack of animal models, absence of long-term basic and clinical studies that might identify benefits of stem cell treatment, and the potential for development of tumors are considered.
- 25 December 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 30 (1) , 247
Erratum to: Acute liver failure-induced hepatic encephalopathy is associated with changes in microRNA expression profiles in cerebral cortex of the mouse
- 25 December 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 30 (1) , 247
Erratum to: Acute liver failure-induced hepatic encephalopathy is associated with changes in microRNA expression profiles in cerebral cortex of the mouse
- 9 October 2014
- Published by Springer Nature in Neurochemical Research
- Vol. 40 (2) , 353-361
Thiamine Deficiency: An Update of Pathophysiologic Mechanisms and Future Therapeutic Considerations
Thiamine is an essential vitamin that is necessary to maintain the functional integrity of cells in the brain. Its deficiency is the underlying cause of Wernicke’s encephalopathy (WE), a disorder primarily associated with, but not limited to, chronic alcoholism. Thiamine deficiency leads to the development of impaired energy metabolism due to mitochondrial dysfunction in focal regions of the brain resulting in cerebral vulnerability. The consequences of this include oxidative stress, excitotoxicity, inflammatory responses, decreased neurogenesis, blood–brain barrier disruption, lactic acidosis and a reduction in astrocyte functional integrity involving a loss of glutamate transporters and other astrocyte-specific proteins which together contribute in a major way to the resulting neurodegeneration. Exactly how these factors acting in concert lead to the demise of neurons is unclear. In this review we reassess their relative importance in the light of more recent findings and discuss therapeutic possibilities that may provide hope for the future for individuals with WE.
- 9 October 2014
- Published by Springer Nature in Neurochemical Research
- Vol. 40 (2) , 353-361
Thiamine Deficiency: An Update of Pathophysiologic Mechanisms and Future Therapeutic Considerations
Thiamine is an essential vitamin that is necessary to maintain the functional integrity of cells in the brain. Its deficiency is the underlying cause of Wernicke’s encephalopathy (WE), a disorder primarily associated with, but not limited to, chronic alcoholism. Thiamine deficiency leads to the development of impaired energy metabolism due to mitochondrial dysfunction in focal regions of the brain resulting in cerebral vulnerability. The consequences of this include oxidative stress, excitotoxicity, inflammatory responses, decreased neurogenesis, blood–brain barrier disruption, lactic acidosis and a reduction in astrocyte functional integrity involving a loss of glutamate transporters and other astrocyte-specific proteins which together contribute in a major way to the resulting neurodegeneration. Exactly how these factors acting in concert lead to the demise of neurons is unclear. In this review we reassess their relative importance in the light of more recent findings and discuss therapeutic possibilities that may provide hope for the future for individuals with WE.
- 29 June 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 29 (4) , 889-890
Mechanisms of hepatic encephalopathy and thiamine deficiency
- 29 June 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 29 (4) , 889-890
Mechanisms of hepatic encephalopathy and thiamine deficiency
- 15 June 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 29 (4) , 1061-1068
Role of astrocytes in thiamine deficiency
Thiamine deficiency (TD) is the underlying cause of Wernicke’s encephalopathy (WE), an acute neurological disorder characterized by structural damage to key periventricular structures in the brain. Increasing evidence suggests these focal histological lesions may be representative of a gliopathy in which astrocyte-related changes are a major feature of the disorder. These changes include a loss of the glutamate transporters GLT-1 and GLAST concomitant with elevated interstitial glutamate levels, lowered brain pH associated with increased lactate production, decreased levels of GFAP, reduction in the levels of glutamine synthetase, swelling, alterations in levels of aquaporin-4, and disruption of the blood–brain barrier. This review focusses on how these manifestations contribute to the pathophysiology of TD and possibly WE.
- 15 June 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 29 (4) , 1061-1068
Role of astrocytes in thiamine deficiency
Thiamine deficiency (TD) is the underlying cause of Wernicke’s encephalopathy (WE), an acute neurological disorder characterized by structural damage to key periventricular structures in the brain. Increasing evidence suggests these focal histological lesions may be representative of a gliopathy in which astrocyte-related changes are a major feature of the disorder. These changes include a loss of the glutamate transporters GLT-1 and GLAST concomitant with elevated interstitial glutamate levels, lowered brain pH associated with increased lactate production, decreased levels of GFAP, reduction in the levels of glutamine synthetase, swelling, alterations in levels of aquaporin-4, and disruption of the blood–brain barrier. This review focusses on how these manifestations contribute to the pathophysiology of TD and possibly WE.
- 1 June 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 448 (3) , 335-341
Thiamine deficiency results in release of soluble factors that disrupt mitochondrial membrane potential and downregulate the glutamate transporter splice-variant GLT-1b in cultured astrocytes
- 1 June 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 448 (3) , 335-341
Thiamine deficiency results in release of soluble factors that disrupt mitochondrial membrane potential and downregulate the glutamate transporter splice-variant GLT-1b in cultured astrocytes
- 27 May 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 29 (4) , 891-899
Acute liver failure-induced hepatic encephalopathy is associated with changes in microRNA expression profiles in cerebral cortex of the rat
The mechanisms that promote brain dysfunction after acute liver failure (ALF) are not clearly understood. The small noncoding RNAs known as microRNAs (miRNAs) significantly control mRNA translation and thus normal and pathological functions in the mammalian body. To understand their significance in ALF, we currently profiled the expression of miRNAs in the cerebral cortex of mice sacrificed at coma stage following treatment with azoxymethane. Of the 470 miRNAs profiled using microarrays, 37 were significantly altered (20 up-and 17 down-regulated) in their expression in the ALF group compared to sham group. In silico analysis showed that the ALF-responsive miRNAs target on average 231 mRNAs/miRNA (range: 3 to 840 targets). Pathways analysis showed that many miRNAs altered after ALF target multiple mRNAs that are part of various biological and molecular pathways. Glutamatergic synapse, Wnt signaling, MAP-kinase signaling, axon guidance, PI3-kinase-AKT signaling, T-cell receptor signaling and ubiquitin-mediated proteolysis are the top pathways targeted by the ALF-sensitive miRNAs. At least 28 ALF-responsive miRNAs target each of the above pathways. We hypothesize that alterations in miRNAs and their down-stream mRNAs of signaling pathways might play a role in the induction and progression of neurological dysfunction observed during ALF.
- 27 May 2014
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 29 (4) , 891-899
Acute liver failure-induced hepatic encephalopathy is associated with changes in microRNA expression profiles in cerebral cortex of the rat
The mechanisms that promote brain dysfunction after acute liver failure (ALF) are not clearly understood. The small noncoding RNAs known as microRNAs (miRNAs) significantly control mRNA translation and thus normal and pathological functions in the mammalian body. To understand their significance in ALF, we currently profiled the expression of miRNAs in the cerebral cortex of mice sacrificed at coma stage following treatment with azoxymethane. Of the 470 miRNAs profiled using microarrays, 37 were significantly altered (20 up-and 17 down-regulated) in their expression in the ALF group compared to sham group. In silico analysis showed that the ALF-responsive miRNAs target on average 231 mRNAs/miRNA (range: 3 to 840 targets). Pathways analysis showed that many miRNAs altered after ALF target multiple mRNAs that are part of various biological and molecular pathways. Glutamatergic synapse, Wnt signaling, MAP-kinase signaling, axon guidance, PI3-kinase-AKT signaling, T-cell receptor signaling and ubiquitin-mediated proteolysis are the top pathways targeted by the ALF-sensitive miRNAs. At least 28 ALF-responsive miRNAs target each of the above pathways. We hypothesize that alterations in miRNAs and their down-stream mRNAs of signaling pathways might play a role in the induction and progression of neurological dysfunction observed during ALF.